Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications
- Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry
- Technology to be used in Illumina’s next-generation sequencing (NGS) products
AMSTERDAM, THE NETHERLANDS, 4 December 2024 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index and beyond, today announced it has entered into a licensing agreement with Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. The agreement grants Illumina access to Synaffix’s patented metal-free click chemistry technology.
Synaffix’s patented metal-free click chemistry will be used in relation to certain Illumina next-generation sequencing (NGS) products.
